


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Aug-2022
Document Type: USP Monographs
DocId: GUID-DB1F177F-EF43-44DB-9DC7-7319938CD63C_5_en-US
DOI: https://doi.org/10.31003/USPNF_M82370_05_01
DOI Ref: d1cm8

© 2025 USPC
Do not distribute

Thiabendazole



$C_{10}H_7N_3S$ 201.25

1*H*-Benzimidazole, 2-(4-thiazolyl)-;

2-(4-Thiazolyl)benzimidazole CAS RN®: 148-79-8; UNII: N1Q45E87DT.

Change to read:

DEFINITION

Thiabendazole contains NLT 98.0% and NMT 101.0% of thiabendazole ($C_{10}H_7N_3S$), calculated on the dried basis.

[NOTE—Thiabendazole labeled solely for veterinary use is exempt from the requirements of the tests for [Residue on Ignition \(281\)](#)▲ (USP 1-Aug-2022) and *Organic Impurities*.]

IDENTIFICATION

Change to read:

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197K. Do not dry▲ the Standard nor the Sample.▲ (USP 1-Aug-2022)

Change to read:

- **B.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Ultraviolet-Visible Spectroscopy](#): 197U

▲ **Standard solution:** 5 µg/mL of [USP Thiabendazole RS](#) in 0.1 N [hydrochloric acid](#)▲ (USP 1-Aug-2022)

Sample solution: 5 µg/mL in 0.1 N [hydrochloric acid](#)

Acceptance criteria: Meets the requirements

- **C.**

Solution A: Dissolve 20 g of [ferric ammonium sulfate](#) in 75 mL of [water](#), add 10 mL of 1 N [sulfuric acid](#), and dilute with [water](#) to 100 mL.

Sample: 5 mg of Thiabendazole

Analysis: Dissolve the *Sample* in 5 mL of 0.1 N [hydrochloric acid](#), add 3 mg of *p*-phenylenediamine dihydrochloride, and shake to dissolve.

Add 0.1 g of zinc dust, mix, and allow to stand for 2 min. Add 5 mL of *Solution A*.

Acceptance criteria: A blue or blue-violet color develops.

- **D.** The R_f value of the principal spot of the *Identification solution* corresponds to that of *Standard solution A*, as obtained in the test for *Organic Impurities*.

ASSAY

- **PROCEDURE**

Sample: 160 mg of Thiabendazole

Analysis: Dissolve the *Sample* in 10 mL of [glacial acetic acid](#). Add 50 mL of [acetic anhydride](#), 1 mL of [mercuric acetate TS](#), and 2 drops of [crystal violet TS](#). Titrate with 0.1 N perchloric acid VS (the color change at the endpoint is from blue to blue-green). Perform a blank determination, and make any necessary correction. Each milliliter of 0.1 N perchloric acid is equivalent to 20.13 mg of thiabendazole ($C_{10}H_7N_3S$).

Acceptance criteria: 98.0%–101.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Delete the following:

▲ **SELENIUM (291)****Sample:** 200 mg of Thiabendazole**Acceptance criteria:** NMT 0.003%▲ (USP 1-Aug-2022)• **ORGANIC IMPURITIES****Standard stock solution:** 1.0 mg/mL of [USP Thiabendazole RS](#) in [glacial acetic acid](#)**Standard solutions:** Dilute *Standard stock solution* as per [Table 1](#) with [glacial acetic acid](#) to obtain *Standard solutions A, B, and C* having the following compositions:**Table 1**

Standard solution	Dilution	Concentration (µg/mL)	Percentage (% for Comparison with Sample)
A	1 in 4	250	0.5
B	3 in 20	150	0.3
C	1 in 20	50	0.1

Sample solution: 50 mg/mL of Thiabendazole in [glacial acetic acid](#)**Identification solution:** 0.25 mg/mL of Thiabendazole in [glacial acetic acid](#), from *Sample solution***Chromatographic system**(See [Chromatography \(621\)](#), [General Procedures](#), [Thin-Layer Chromatography](#).)**Mode:** TLC**Adsorbent:** 0.25-mm layer of chromatographic silica gel mixture**Application volume:** 10 µL**Developing solvent system:** [Toluene](#), [glacial acetic acid](#), [acetone](#), and [water](#) (60:20:8:2)**Analysis****Samples:** *Standard solutions, Sample solution, and Identification solution*

Develop in the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Examine the plate under short-wavelength UV light, and compare the intensities of any secondary spots observed in the chromatogram of the *Sample solution* with those of the principal spots in the chromatograms of the *Standard solutions*.

Acceptance criteria: No secondary spot from the chromatogram of the *Sample solution* is larger or more intense than the principal spot of the *Standard solution* (NMT 0.5%), and the sum of the intensities of all secondary spots of the *Sample solution* corresponds to NMT 1.0%.

SPECIFIC TESTS• **MELTING RANGE OR TEMPERATURE (741):** 296°–303°• **LOSS ON DRYING (731)****Sample:** Dry in vacuum at 100° for 2 h.**Acceptance criteria:** NMT 0.5%**ADDITIONAL REQUIREMENTS**• **PACKAGING AND STORAGE:** Preserve in well-closed containers.• **USP REFERENCE STANDARDS (11).**[USP Thiabendazole RS](#)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
THIABENDAZOLE	Documentary Standards Support	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 47(2)

Current DocID: GUID-DB1F177F-EF43-44DB-9DC7-7319938CD63C_5_en-US

DOI: https://doi.org/10.31003/USPNF_M82370_05_01

DOI ref: [d1cm8](#)

OFFICIAL